Trial · NCT06554028
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028, Phase 2, Not yet recruiting, Henan Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer. Trials, record NCT06554028. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06554028
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
- NCT number
- NCT06554028
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Henan Cancer Hospital
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Interventions
- chemotherapy TP regimen combined with Tislelizumab
- First posted
- 2024-08-14
- Last updated
- 2024-08-14
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Laryngeal preservation rate at 3 months after radiotherapy | 3-month post-radiotherapy | defined as the absence of any residual disease that would justify salvage total laryngectomy |
| Secondary | Objective response rate after induction chemoimmunotherapy | 2 weeks after the end of cycle 3 of induction therapy | 2 weeks after the 3th cycle of induction therapy |
| Secondary | Overall survival rate at 1 year | One year post-radiotherapy | Overall survival rate at 1 year |
| Secondary | Laryngeal preservation rate at 1 year after radiotherapy | 1 year post-radiotherapy | defined as the absence of any residual disease that would justify salvage total laryngectomy |
| Secondary | Progression-free survival rate at 1 year | One year post-radiotherapy | Progression-free survival rate at 1 year |
| Secondary | Pathological complete response rate of the patients receiving surgical resection | Within 3 weeks after surgery | Pathological complete response rate of the patients receiving surgical resection, evaluated by experienced pathologists |
| Secondary | Overall survival rate at 2 year | Two year post-radiotherapy | Overall survival rate at 2 year |
| Secondary | Progression-free survival rate at 2 year | Two year post-radiotherapy | Progression-free survival rate at 2 year |
| Secondary | Laryngeal Preservation rate at 2 year | Laryngeal Preservation rate at 2 year | Two year post-radiotherapy |
| Secondary | Adverse Effect | One year post-radiotherapy | Adverse Effect, evaluated by CTCAE 4.0.03 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06554028
GET https://conductscience.org/api/trials/v1/NCT06554028/registered